日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

可切除黑色素瘤新辅助治疗中,PD-1 和 LAG-3 靶向双特异性抗体与其他免疫检查点抑制剂联合疗法:一项随机 1b/2 期 Morpheus-Melanoma 试验

Long, Georgina V; Nair, Nitya; Marbach, Daniel; Scolyer, Richard A; Wilson, Sabine; Cotting, Denise; Staedler, Nicolas; Amaria, Rodabe N; Ascierto, Paolo Antonio; Tarhini, Ahmad A; Robert, Caroline; Hamid, Omid; Gaudy-Marqueste, Caroline; Lebbe, Celeste; Munoz-Couselo, Eva; Menzies, Alexander M; Pages, Cecile; Curigliano, Giuseppe; Mandala, Mario; Jessop, Nikki; Bader, Uwe; Perdicchio, Maurizio; Teichgräber, Volker; Muecke, Merlind; Markert, Christoph; Blank, Christian

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma

免疫细胞因子 Simlukafusp Alfa (FAP-IL2v) 联合 Pembrolizumab 治疗晚期和/或转移性黑色素瘤的 Ib 期研究

Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V Long, Miguel F Sanmamed, Anna Spreafico, Elizabeth Buchbinder, Mario Sznol, Hans Prenen, Alexander Fedenko, Mohammed Milhem, Ana Maria Arance Fernandez, Jean-Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, 

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

帕博利珠单抗治疗局部晚期、复发性或转移性皮肤鳞状细胞癌患者的健康相关生活质量:KEYNOTE-629

Bratland, Åse; Munoz-Couselo, Eva; Mortier, Laurent; Roshdy, Osama; González, Rene; Schachter, Jacob; Arance, Ana M; Grange, Florent; Meyer, Nicolas; Joshi, Abhishek Jagdish; Billan, Salem; Hughes, Brett G M; Grob, Jean-Jacques; Ramakrishnan, Karthik; Ge, Joy; Gumuscu, Burak; Swaby, Ramona F; Gutzmer, Ralf